Commonly used dementia drugs can help more patients with Alzheimer's

March 7, 2012, King's College London

The dementia drug donepezil (Aricept), already widely used to treat mild to moderate Alzheimer's disease, can also help in moderate to severe patients, according to a report funded by the UK Medical Research Council (MRC) and the Alzheimer's Society. The study suggests that extending treatment to this group could help treat twice as many sufferers worldwide. Encouragingly, the drug has greater positive benefits for patients more severely affected than for those in the earlier stages of dementia.

It is estimated that 18 million people worldwide suffer from , which is the most common cause of . According to the , of the 35 million people currently living with dementia globally, 58% live in low- and middle-income countries and by 2050 this figure is projected to reach 71% of the total.

The multi-centre UK study, led by Professor Robert Howard at King's College London, is the first trial to demonstrate the value of continued for those patients with moderate to severe Alzheimer's disease who have deteriorated beyond the point where donepezil is currently recommended.

The study, to be published in the , looked at two drugs: donepezil and memantine. Donepezil is the most commonly prescribed of the and is recommended for patients at the earliest stages of Alzheimer's disease. Doctors are currently advised to stop prescribing donepezil when the disease progresses to become moderate to severe and until now there has been no clear evidence that continuing treatment is of benefit to patients.

Over the course of the trial, patients who continued to take donepezil showed considerably less decline in cognition – memory, orientation, language function – and function (retained ability to carry out simple daily tasks and self-care) than those taking a placebo drug. The benefits seen with continued treatment were clinically important and were greater than those previously seen in patients with less severe Alzheimer's disease. Whilst the effect was slightly smaller, starting memantine treatment also resulted in significantly better cognitive and functional abilities compared with those taking a placebo.

Professor Robert Howard, lead author from the Institute of Psychiatry at King's says: "As patients progress to more severe forms of Alzheimer's disease, clinicians are faced with a difficult decision as to whether to continue or not with dementia drugs and, until now, there has been little evidence to guide that decision. For the first time, we have robust and compelling evidence that treatment with these drugs can continue to help patients at the later, more severe stages of the disease. We observed that patients who continued taking donepezil were better able to remember, understand, communicate and perform daily tasks for at least a year longer than those who stopped taking the drugs. These improvements were noticeable to patients, their caregivers and doctors. Both donepezil and will soon be off patent and available in very cheap generic preparations. These findings will greatly increase the numbers of patients in the developed and developing world that we are able to treat."

Professor Nick Fox, MRC Senior Clinical Fellow at the Institute of Neurology, University College London, says: "The number of people with Alzheimer's disease and other forms of dementia is reaching critical levels. It has never been more important to invest in research which will enable doctors to make informed decisions based on the best evidence possible when deciding what treatments to give . The MRC has an ongoing commitment to the development of effective, safe treatments that will improve the quality of life for people with Alzheimer's disease and their care givers."

Professor Clive Ballard, Director of Research at Alzheimer's Society, says: "Thanks to the Alzheimer's drug donepezil, tens of thousands of people in the early to moderate stages of the condition are able to recognise their family for longer, play with their grandchildren and make vital plans for the future. This major new trial now shows that there could also be significant benefits on continuing the treatment into the later stages too. There are 750,000 people with dementia in the UK yet currently prescription levels of Alzheimer's drugs are still low. If this is to change we have to improve the shocking diagnosis rates and ensure everyone is given the opportunity to try treatments."

Explore further: Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease

More information: Howard et al 'Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease' is published in New England Journal of Medicine.

WHO information on dementia epidemic in Asia:

Related Stories

Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease

April 11, 2011
An analysis of studies involving the drug memantine finds a lack of evidence for benefit when the drug is used to treat patients with mild Alzheimer disease, according to a report posted online today that will appear in the ...

Memantine drug ineffective against Alzheimer's in Down's syndrome patients

January 11, 2012
(Medical Xpress) -- Memantine, a drug used to treat patients with Alzheimer’s disease, is ineffective for people with Down’s syndrome aged 40 and over, according to a study led by researchers at King’s and ...

Recommended for you

A new way of thinking about tau kinetics, an essential component of Alzheimer's disease

March 21, 2018
Alzheimer's disease is most often characterized by two different pathologies in the brain: plaque deposits of a protein called beta-amyloid and tangles of another protein called tau. A paper appearing March 21 in the journal ...

Could drugs used after an organ transplant protect against Alzheimer's?

March 21, 2018
A UT Southwestern study in mice provides new clues about how a class of anti-rejection drugs used after organ transplants may also slow the progression of early-stage Alzheimer's disease.

Cell therapy could improve brain function for Alzheimer's disease

March 15, 2018
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, ...

Physically fit women nearly 90 percent less likely to develop dementia

March 14, 2018
Women with high physical fitness at middle age were nearly 90 percent less likely to develop dementia decades later, compared to women who were moderately fit, according to a study published the March 14, 2018, online issue ...

Poor sleep may heighten Alzheimer's risk

March 12, 2018
(HealthDay)—Older adults who are sleepy during the day might have harmful plaque building in their brain that is a sign of impending Alzheimer's disease, researchers report.

Dementia patients with distorted memories may actually retain key information – researchers say

March 7, 2018
Some memories containing inaccurate information can be beneficial to dementia sufferers because it enables them to retain key information researchers say.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.